Andrew Hedin is a principal in Bessemer’s Cambridge office where he focuses on investments in healthcare. He is closely involved in companies such as Kymera Therapeutics, Bright Health, Qventus, Artemis Health, TScan Therapeutics, Collective Medical, and Groups.
Prior to joining Bessemer in 2015, Andrew worked at F-Prime Capital, Fidelity’s healthcare-focused venture capital fund, as well as Leerink Partners, where he advised life sciences companies on growth strategies.
He earned an MBA with honors from The Wharton School, where he majored in health care management and finance, as well as a degree in biological basis of behavior from the University of Pennsylvania. He serves as co-chair of the New England Venture Network.